AK104

PD-1/CTLA-4 bispecific antibody · Akeso, Inc.

Drug timelines are a Plus or Pro feature.

59 regulatory and trial events tracked for AK104, covering 2022-08-11 to 2026-04-22. Get the full timeline:

Most recent: Clinical Trial Update: AK104 Plus Radiotherapy Combined With Standard Therapy Versus Standard Therapy as First-Line Treatment for pMMR/MSS CRLM (APSOC) [Phase 2]

See pricing